1057 related articles for article (PubMed ID: 19505575)
1. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
2. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
3. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
4. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
5. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
6. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
8. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Bukhatwa S; Zeng BY; Rose S; Jenner P
Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
11. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
12. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
[TBL] [Abstract][Full Text] [Related]
13. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats.
Miwa H; Kubo T; Suzuki A; Kondo T
Neurosci Lett; 2006 Jun; 401(1-2):146-9. PubMed ID: 16600504
[TBL] [Abstract][Full Text] [Related]
14. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells.
Fan GH; Zhou HY; Yang H; Chen SD
FEBS Lett; 2006 May; 580(13):3091-8. PubMed ID: 16678164
[TBL] [Abstract][Full Text] [Related]
15. Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain.
Andringa G; Bol JG; Wang X; Boekel A; Bennett MC; Chase TN; Drukarch B
Neuropathol Appl Neurobiol; 2006 Apr; 32(2):157-69. PubMed ID: 16599944
[TBL] [Abstract][Full Text] [Related]
16. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein.
Lee HJ; Khoshaghideh F; Lee S; Lee SJ
Eur J Neurosci; 2006 Dec; 24(11):3153-62. PubMed ID: 17156376
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
[TBL] [Abstract][Full Text] [Related]
19. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
Kovacs GG; Milenkovic IJ; Preusser M; Budka H
Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
[TBL] [Abstract][Full Text] [Related]
20. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N; Melamed E; Offen D
Neurosci Lett; 2006 May; 399(1-2):27-32. PubMed ID: 16584840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
